Entry Detail


General Information

Database ID: LDA0004896
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:SMIM30
Full Name:small integral membrane protein 30
Category:LncRNA
Species:Homo sapiens
Synonyms:LINC00998
Chromosome:7
Strand:-
Coordinate:
Start Site(bp):113116718End Site(bp):113118554
External Links:
Ensembl ID:ENSG00000214194
Ensembl Transcript ID:N/A
Entrez Gene:401397.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:4   
More Information
Causal Disease Number:4
Network:
Top Causal Diseases:
Leukemia, Myeloid, Acute  (Score: 0.731059)
Glioblastoma  (Score: 0.731059)
Leukemia, Myeloid, Acute  (Score: 0.731059)
Glioblastoma  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:3068D005909
Disease Name:glioblastomaGlioblastoma
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Alias:GBM//adult glioblastoma multiforme//grade IV adult Astrocytic tumor//primary glioblastoma multiforme//spongioblastoma multiformeGlioblastoma//Glioblastomas//Astrocytoma, Grade IV//Astrocytomas, Grade IV//Grade IV Astrocytoma//Grade IV Astrocytomas//Glioblastoma Multiforme//Giant Cell Glioblastoma//Giant Cell Glioblastomas//Glioblastoma, Giant Cell//Glioblastomas, Giant Cell

 

Disease Association Statistics

Total Associated ncRNA Number:296   
More Information
Causal ncRNA Number:252
Network:
Top Causal ncRNAs:
DLEU1  (Score: 0.999893)
LINC-ROR  (Score: 0.999893)
MALAT1  (Score: 0.999893)
HOTAIRM1  (Score: 0.999893)
LINC-ROR  (Score: 0.999893)
MALAT1  (Score: 0.999893)
HOTAIRM1  (Score: 0.999893)
DLEU1  (Score: 0.999893)
hsa_circ_0029426  (Score: 0.985791)
DLGAP1-AS1  (Score: 0.985791)
More Information

 

Evidence Support

Strong Evidence:RNA Pull-Down//Western Blot//FISH//qRT-PCR//RIP//Luciferase Report Assay//IF
Weak Evidence:

 

Reference

[1] PubMed ID:33268783
Disease Name:Glioblastoma
Sample:glioblastoma tissues
Dysfunction Pattern:regulation[ CBX3-mediated c-Met/Akt/mTOR axis]
Validated Method:RNA Pull-Down//Western Blot//qRT-PCR//RIP//FISH//Luciferase Report Assay//IF
Description:Through screening using TCGA database, we found that LINC00998 was downregulated in glioblastoma tissues and that low expression of LINC00998 was associated with poor prognosis. Mechanistically, RNA pull-down and mass spectrometry results showed an interaction between LINC00998 and CBX3. IP assays demonstrated that LINC00998 could stabilize CBX3 and prevent its ubiquitination degradation. GSEA indicated that LINC00998 could regulate the c-Met/Akt/mTOR signaling pathway, which was further confirmed by a rescue assay using siRNA-mediated knockdown of CBX3 and the Akt inhibitor MK2206. In addition, dual-luciferase assays showed that miR-34c-5p could directly bind to LINC00998 and downregulate its expression.
Causality:Yes
Causal Description: Overexpression of LINC00998 inhibited glioma cell proliferation in vitro and in vivo and blocked the G1/S cell cycle transition, which exerted a tumor-suppressive effect on glioma progression.
Clinical-realted Application: